Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
Immunotherapies are emerging as powerful weapons for the treatment of malignancies. Chimeric antigen receptor (CAR)-engineered T cells have shown dramatic clinical results in patients with hematological malignancies. However, it is still challenging for CAR T cell therapy to be successful in several...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/13/3236 |
| _version_ | 1797528451664576512 |
|---|---|
| author | Chi Hoon Park |
| author_facet | Chi Hoon Park |
| author_sort | Chi Hoon Park |
| collection | DOAJ |
| description | Immunotherapies are emerging as powerful weapons for the treatment of malignancies. Chimeric antigen receptor (CAR)-engineered T cells have shown dramatic clinical results in patients with hematological malignancies. However, it is still challenging for CAR T cell therapy to be successful in several types of blood cancer and most solid tumors. Many attempts have been made to enhance the efficacy of CAR T cell therapy by modifying the CAR construct using combination agents, such as compounds, antibodies, or radiation. At present, technology to improve CAR T cell therapy is rapidly developing. In this review, we particularly emphasize the most recent studies utilizing genetic engineering and synergistic agents to improve CAR T cell therapy. |
| first_indexed | 2024-03-10T09:58:30Z |
| format | Article |
| id | doaj.art-372206b91f37449893d0b0f450785488 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:58:30Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-372206b91f37449893d0b0f4507854882023-11-22T02:06:47ZengMDPI AGCancers2072-66942021-06-011313323610.3390/cancers13133236Making Potent CAR T Cells Using Genetic Engineering and Synergistic AgentsChi Hoon Park0Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Daejeon 34114, KoreaImmunotherapies are emerging as powerful weapons for the treatment of malignancies. Chimeric antigen receptor (CAR)-engineered T cells have shown dramatic clinical results in patients with hematological malignancies. However, it is still challenging for CAR T cell therapy to be successful in several types of blood cancer and most solid tumors. Many attempts have been made to enhance the efficacy of CAR T cell therapy by modifying the CAR construct using combination agents, such as compounds, antibodies, or radiation. At present, technology to improve CAR T cell therapy is rapidly developing. In this review, we particularly emphasize the most recent studies utilizing genetic engineering and synergistic agents to improve CAR T cell therapy.https://www.mdpi.com/2072-6694/13/13/3236CAR T cellgenetic engineeringsynergistic agentscancer |
| spellingShingle | Chi Hoon Park Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents Cancers CAR T cell genetic engineering synergistic agents cancer |
| title | Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents |
| title_full | Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents |
| title_fullStr | Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents |
| title_full_unstemmed | Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents |
| title_short | Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents |
| title_sort | making potent car t cells using genetic engineering and synergistic agents |
| topic | CAR T cell genetic engineering synergistic agents cancer |
| url | https://www.mdpi.com/2072-6694/13/13/3236 |
| work_keys_str_mv | AT chihoonpark makingpotentcartcellsusinggeneticengineeringandsynergisticagents |